相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Urology & Nephrology
Georges El Hasbani et al.
Summary: In rare cases, COVID-19 vaccines can lead to autoimmune diseases, including anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This report presents a case of a 47-year-old woman who developed acute renal failure few days after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine, which was managed using corticosteroids and azathioprine.
Review
Immunology
Yue Chen et al.
Summary: Autoimmune manifestations have been reported in response to certain COVID-19 vaccines, but it is still unclear whether there is a causal relationship. These reports can help guide the clinical assessment and management of autoimmune manifestations after vaccination.
Letter
Dermatology
Marco May Lee et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yan Xie et al.
Summary: Individuals with COVID-19, even those who were not hospitalized during the acute phase of the infection, are at an increased long-term risk of various cardiovascular disorders. A study using national healthcare databases found that beyond the first 30 days after infection, individuals with COVID-19 have an elevated risk of developing cerebrovascular disorders, heart diseases, and other cardiovascular complications. The risk increases depending on the care setting during the acute phase.
Article
Hematology
Frederikus A. Klok et al.
Summary: In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were rapidly developed and introduced, leading to a major impact on the evolution of the disease. However, reports of rare side-effects such as vaccine-induced immune thrombotic thrombocytopenia (VITT) have emerged, requiring prompt testing and treatment with intravenous immunoglobulin and non-heparin anticoagulants.
LANCET HAEMATOLOGY
(2022)
Letter
Urology & Nephrology
Aaron Shengting Mai et al.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Rheumatology
Luis J. Jara et al.
Summary: Around 60% of the global population has been vaccinated against SARS-CoV-2, leading to a significant reduction in the impact of the pandemic and the resumption of social and economic activities. Studies have shown that the vaccines are effective and safe in various populations, including those with risk factors or immunocompromised individuals. While a minority of people may experience adverse events, including autoimmune syndromes, the exact mechanisms for their development are still being studied. Rheumatologists need to be vigilant in monitoring these autoimmune syndromes and investigating their relationship to vaccination timing.
CLINICAL RHEUMATOLOGY
(2022)
Article
Medicine, General & Internal
Hiroshi Shimagami et al.
Summary: Exacerbation of rheumatic disease has been reported after SARS-CoV-2 vaccination, although there are few cases of new-onset rheumatic diseases. We present two cases of new-onset persistent polyarthritis following mRNA vaccination against SARS-CoV-2. One patient developed bilateral pleural effusions with significantly elevated serum interferon (IFN)-beta levels, while the other patient had no effusion and serum IFN-beta levels comparable to healthy individuals. Treatment with 20 mg prednisolone was effective for both patients. Although further investigations are needed, the marked increase in serum IFN-beta levels observed in the patient with pleural effusion may suggest an excessive response from the innate immune system to mRNA vaccines.
Letter
Surgery
Liam Birkett et al.
AESTHETIC SURGERY JOURNAL
(2022)
Article
Microbiology
Rima Hajjo et al.
Summary: COVID-19 vaccines have played a crucial role in reducing infections and deaths, but large-scale vaccination can lead to heterogeneity in immune responses and adverse reactions. This study used a systems biology approach to investigate the pharmacological effects of mRNA vaccines, finding that they affect immune response pathways and calcium homeostasis, potentially leading to adverse events.
Article
Immunology
Isabel Garrido et al.
Summary: The case of acute severe autoimmune hepatitis following COVID-19 vaccination highlights the importance of closely monitoring adverse reactions during the vaccination process to ensure safety. Healthcare providers must remain vigilant during mass COVID-19 vaccination to detect and manage potential complications promptly.
JOURNAL OF AUTOIMMUNITY
(2021)
Review
Pharmacology & Pharmacy
Yvette N. Lamb
Summary: BNT162b2, a lipid nanoparticle-formulated mRNA vaccine encoding the SARS-CoV-2 spike protein, has received emergency use authorization in multiple countries for individuals aged 16 and older to prevent COVID-19.
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Immunology
Karolina Akinosoglou et al.
CLINICAL IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.
Article
Endocrinology & Metabolism
Olga Vera-Lastra et al.
Summary: Two female health care workers developed clinical manifestations of thyroid hyperactivity, increased thyroid hormone levels, suppressed thyroid-stimulating hormone, and elevated antithyroid antibodies three days after receiving a SARS-CoV-2 vaccine. This indicates a potential link between SARS-CoV-2 vaccination and the onset of autoimmune thyroid diseases like Graves' disease.
Article
Rheumatology
Victoria Furer et al.
Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Editorial Material
Allergy
Mary M. Tomayko et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Letter
Immunology
Aristo Vojdani et al.
CLINICAL IMMUNOLOGY
(2020)
Article
Medicine, General & Internal
A. Richard Kitching et al.
NATURE REVIEWS DISEASE PRIMERS
(2020)
Review
Immunology
Yahel Segal et al.
CELLULAR & MOLECULAR IMMUNOLOGY
(2018)
